Lipoproteins in inflammation and sepsis. I. Basic science.
BACKGROUND
High-density lipoproteins (HDL) have been shown to bind and neutralize lipopolysaccharide (LPS) and are regarded as possible therapeutic agents for sepsis and conditions associated with local or systemic inflammation. However, in recent years, a multitude of possible immunomodulatory properties other than LPS neutralization have become evident.


CONCLUSIONS
This review highlights the advances in the understanding of how HDL is protective in both in vitro and in vivo inflammatory settings, including the ability of HDL to modulate adhesion molecule expression, upregulate endothelial nitric oxide synthase and counteract oxidative stress. Also, the active components of HDL and the recent discovery of novel lipid modulators of inflammation are discussed.
Murch
Oliver
O
St. Bartholomew's and The Royal London School of Medicine and Dentistry, Queen Mary University of London, Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, London, UK.
Collin
Marika
M
Hinds
Charles J
CJ
Thiemermann
Christoph
C
D000818:Animals; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D018805:Sepsis / Q000276:immunology / Q000378:metabolism*
D008075:Lipoproteins, HDL